Adipositas

A new analysis of clinical trials indicates that semaglutide, the active ingredient in Ozempic and Wegovy, helps older adults with obesity lose substantial weight and improve heart health markers. The findings come from data on participants aged 65 and above who received the once-weekly medication alongside lifestyle changes.

11. Mai 2026 Von KI berichtet Fakten geprüft

An international meta-analysis slated for presentation at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey (May 12–15) suggests that people who increase their walking to roughly 8,500 steps a day during a weight-loss program and sustain similar levels afterward may be less likely to regain weight.

An Italian research team comparing standard BMI categories with dual-energy X-ray absorptiometry (DXA) body-fat measurements found that more than one-third of adults were placed in the wrong weight category, and that BMI slightly overestimated the combined prevalence of overweight and obesity in the sample.

1. April 2026 Von KI berichtet

The US Food and Drug Administration approved Foundayo, a new once-daily pill for obesity treatment, on Wednesday. Eli Lilly, the manufacturer, also produces the weight-loss injection Zepbound. The approval positions Foundayo as the second obesity pill cleared by the FDA.

New research shows that visceral fat around the waist increases heart failure risk more than BMI, even among those with normal weight. Inflammation mediates much of this link. The findings were presented at the American Heart Association's EPI|Lifestyle Scientific Sessions 2026 in Boston.

17. März 2026 Von KI berichtet

A Hong Kong government report shows about 94% of students do not get enough daily exercise, with 17.5% overweight. It also flags low fruit and vegetable intake, poor vision health and excessive recreational screen time among students.